Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 13 points (-0.1%) at 18,461 as of Wednesday, July 27, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,210 issues advancing vs. 1,692 declining with 152 unchanged.

The Health Care sector currently sits up 1.4% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the sector include Globus Medical ( GMED), down 13.9%, Universal Health Services ( UHS), down 5.6%, Acadia Healthcare ( ACHC), down 4.9%, C.R. Bard ( BCR), down 4.1% and Quintiles Transnational Holdings ( Q), down 3.7%. Top gainers within the sector include Illumina ( ILMN), up 7.8%, Seattle Genetics ( SGEN), up 6.5%, Regeneron Pharmaceuticals ( REGN), up 2.6%, Celgene ( CELG), up 2.0% and Allergan ( AGN), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Boston Scientific ( BSX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Boston Scientific is down $0.39 (-1.6%) to $23.59 on light volume. Thus far, 3.7 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $23.53-$24.11 after having opened the day at $23.99 as compared to the previous trading day's close of $23.98.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $32.2 billion and is part of the health services industry. Shares are up 30.0% year-to-date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Boston Scientific Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Anthem ( ANTM) is down $3.17 (-2.3%) to $134.42 on heavy volume. Thus far, 1.8 million shares of Anthem exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $132.00-$137.98 after having opened the day at $133.50 as compared to the previous trading day's close of $137.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. Anthem has a market cap of $36.8 billion and is part of the health services industry. Shares are down 1.3% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Anthem a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Anthem as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Anthem Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Aetna ( AET) is down $1.20 (-1.0%) to $116.06 on average volume. Thus far, 1.4 million shares of Aetna exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $114.24-$117.13 after having opened the day at $116.71 as compared to the previous trading day's close of $117.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $41.3 billion and is part of the health services industry. Shares are up 8.4% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Aetna a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Aetna Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).